CAT panel questions GSK counsel on by-object restrictions

A lawyer acting for GlaxoSmithKline today argued that the company’s patent settlements with two generic drugmakers cannot be painted as by-object restrictions of competition – but faced questions on his approach by members of the Competition Appeal Tribunal.

Unlock unlimited access to all Global Competition Review content